HRT may lower risk of repeat knee/hip replacement

Article

Taking hormone replacement therapy (HRT) for at least 6 months after total knee arthroplasty (TKA) or total hip arthroplasty (THA) may reduce risk of repeat surgery. So say the results of a community-based cohort study of women in the UK who had undergone TKA or THA for osteoarthritis.

 

Taking hormone replacement therapy (HRT) for at least 6 months after total knee arthroplasty (TKA) or total hip arthroplasty (THA) may reduce risk of repeat surgery. So say the results of a community-based cohort study of women in the UK who had undergone TKA or THA for osteoarthritis.

Published in Annals of the Rheumatic Diseases, the population-based study looked at outcomes in 10,800 women aged ≥40 who had undergone TKA or THA between 1986 and 2006. None of the participants had a history of previous hip fracture or rheumatoid arthritis; 2,700 had taken HRT for ≥6 months whereas 8,100 had not.

At median observation of 3.3 years after TKA/THA, researchers from the University of Oxford reported a hazard ratio (HR) for need for repeat surgery of 0.62 (95% CI 0.41 to 0.94) in those who had taken HRT for ≥6 months versus 0.48 (0.29 to 0.78) in those who had taken it for ≥12 months. Rates of revision were even lower the longer a woman took HRT and the better she adhered to it. Taking HRT before surgery, however, did not influence implant survival.

The findings, which the authors say show a link between HRT use and an almost 40% reduction in revision rates after TKA/THA, require replication in external cohorts and experimental studies. 

 

 

To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Susan Khalil, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Megan Wasson, DO, FACOG
Wasson and Colak
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
Non-hormonal treatments offer relief for genitourinary syndrome of menopause | Image Credit: providers.uthscsa.edu.
Jill Liss, MD, MSCP, FACOG, associate clinical professor, OB/GYN, at the University of Colorado School of Medicine.
Chemen M. Neal, MD, discusses weekly secnidazole for bacterial vaginosis treatment | Image Credit: medicine.iu.edu
Elizabeth Gandee, APRN-CNP, highlights gaps in women's menopause knowledge | Image Credit: wexnermedical.osu.edu
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
Related Content
© 2025 MJH Life Sciences

All rights reserved.